Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¼Ò¾ÆȯÀÚ¿¡¼­ midazolam Á¤ÁÖ ¹× ¾Æ»êÈ­Áú¼Ò ÈíÀÔÁøÁ¤¹ý ÇÏ Ä¡°úÄ¡·áÀÇ Æ¯¼º

Characteristics of Intravenous Midazolam Sedation with Nitrous Oxide in Pediatric Dental Treatment

´ëÇѼҾÆÄ¡°úÇÐȸÁö 2020³â 47±Ç 1È£ p.53 ~ 61
±èÇöÅÂ, ¼ÛÁö¼ö, ÇöÈ«±Ù, ±è¿µÀç, ±èÁ¤¿í, Àå±âÅÃ, ÀÌ»óÈÆ, ½ÅÅÍÀü,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÇöÅ ( Kim Hyun-Tae ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
¼ÛÁö¼ö ( Song Ji-Soo ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
ÇöÈ«±Ù ( Hyun Hong-Keun ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
±è¿µÀç ( Kim Young-Jae ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
±èÁ¤¿í ( Kim Jung-Wook ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
Àå±âÅà( Jang Ki-Taeg ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
ÀÌ»óÈÆ ( Lee Sang-Hoon ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç
½ÅÅÍÀü ( Shin Teo-Jeon ) - ¼­¿ï´ëÇб³ Ä¡ÀÇÇдëÇпø ¼Ò¾ÆÄ¡°úÇб³½Ç

Abstract

MidazolamÀº ´Ü±â ÀÛ¿ë benzodiazepine °è¿­ÀÇ ¾à¹°·Î¼­ ¼Ò¾ÆÄ¡°ú ¿µ¿ªÀÇ ÁøÁ¤Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ´Ù. ÇÏÁö¸¸ ¼Ò¾ÆȯÀÚÀÇ Ä¡°úÄ¡·á½Ã Á¤ÁÖÁøÁ¤¹ýÀ¸·Î¼­ÀÇ midazolamÀÇ ÀÓ»óÀûÀÎ È¿°ú´Â ¿¬±¸°¡ ºÎÁ·ÇÑ ½ÇÁ¤ÀÌ´Ù. À̹ø ¿¬±¸¿¡¼­´Â ¼Ò¾ÆȯÀÚÀÇ Ä¡°úÄ¡·á½Ã midazolam Á¤ÁÖÁøÁ¤¹ý ¹× ¾Æ»êÈ­Áú¼Ò ÈíÀÔÁøÁ¤¹ýÀÇ È¿°ú¿Í ¾ÈÁ¤¼º¿¡ ´ëÇØ ÈÄÇâÀûÀÎ ºÐ¼®À» ½ÃÇàÇÏ¿´´Ù. Midazolam Á¤ÁÖ ¹× ¾Æ»êÈ­Áú¼Ò ÈíÀÔÁøÁ¤¹ý ÇÏ Ä¡°úÄ¡·á¸¦ ½ÃÇàÇÑ 115¸í(118·Ê)¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. Àα¸Åë°èÇÐÀû ¿ä¼Ò, ȯÀÚÀÇ Àü½Å»óÅÂ, ÁøÁ¤½Ã°£, midazolam ¹× ¾Æ»êÈ­Áú¼ÒÀÇ ¿ë·®, ÁøÁ¤¹ýÀÇ ¼º°ø·ü¿¡ ´ëÇØ ÀüÀÚÀǹ«±â·ÏÀ» ÅëÇØ Á¶»çÇÏ¿´´Ù. ÁøÁ¤¹ýÀº ÇൿÁ¶ÀýÀ» ¸ñÀûÀ¸·Î ÁÖ·Î »ç¿ëµÇ¾ú´Ù. Æò±Õ ÁøÁ¤ ½Ã°£Àº ¼ö¼ú Ä¡·áÀÇ °æ¿ì 56.7ºÐ, ¼öº¹ Ä¡·áÀÇ °æ¿ì 74.4ºÐÀ̾ú´Ù. Á¤¸Æ³» midazolamÀÇ Ãʱâ Åõ¿©·®Àº 0.051 ¡¾ 0.019 mg/kgÀ̾ú´Ù. 34°Ç(28.8%)¿¡¼­ Ä¡·á Áß 0.036 ¡¾ 0.057 mg/kgÀÇ Ãß°¡ÀûÀÎ midazolam ÀÇ Åõ¿©¸¦ ½ÃÇàÇÏ¿´´Ù. ¾Æ»êÈ­Áú¼ÒÀÇ ³óµµ´Â 40 - 50%·Î À¯ÁöµÇ¾ú´Ù. ÁøÁ¤¹ýÀÇ ¼º°ø·üÀº 99%(n = 117)¿´´Ù. 1 °ÇÀÇ Áõ·Ê¿¡¼­ ÈĵΠ°æ·ÃÀÌ ¹ß»ýÇÏ¿´°í ÀÌ·Î ÀÎÇÑ Ä¡·á Áß´Ü ÈÄ È¯ÀÚ´Â benzodiazepine ±æÇ×Á¦ÀÎ flumazenilÀ¸·Î °¡¿ªµÇ¾ú´Ù. ÀÌ ¿¬±¸¿¡¼­´Â ¾Æ»êÈ­Áú¼Ò ÈíÀÔÁøÁ¤À» µ¿¹ÝÇÑ midazolam Á¤ÁÖÁøÁ¤¹ýÀÌ ÀÓ»óÀûÀ¸·Î È¿°úÀûÀÎ °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ¼º°øÀûÀÎ ÁøÁ¤¹ýÀ»À§Çؼ­ ¸ðµç °úÁ¤ÀÌ ÈƷùÞÀº Àü¹®Àη¿¡ ÀÇÇØ ½ÃÇàµÇ¾î¾ß ÇÏ°í °¡À̵å¶óÀÎÀ» ¹ÙÅÁÀ¸·Î ÇÑ ÀûÀýÇÑ È¯ÀÚ ¼±ÅÃÀÌ ÇÊ¿äÇÏ´Ù.

Midazolam is a short-acting benzodiazepine that is widely used in pediatric dental sedation. However, its clinical effectiveness as an intravenous sedative agent in children has not been widely documented. A retrospective study was conducted to evaluate the efficacy and safety of intravenous midazolam and nitrous oxide inhalation sedation in pediatric dental treatment. The subjects were 115 patients (118 cases) who received dental treatment under intravenous midazolam and nitrous oxide inhalation sedation. Demographic factors, general health status, sedation time, midazolam and nitrous oxide dosage, and success rate of sedation were evaluated from electronic medical records. Behavioral management was the main reason of choosing sedation. Mean duration of sedation was 56.7 minutes for surgical treatment, and 74.4 minutes for restorative treatment. The initial dosage of intravenous midazolam was 0.051 ¡¾ 0.019 mg/kg. In 34 cases (28.8%), additional midazolam of 0.036 ¡¾ 0.057 mg/kg was delivered during the treatment. The concentration of nitrous oxide was maintained between 40% and 50%. The success rate of sedation was 99% (n = 117). In 1 case, laryngospasm occurred and the patient was reversed with benzodiazepine antagonist, flumazenil. Intravenous midazolam sedation with nitrous oxide was shown to be clinically effective for the dental treatment in children, if administered by trained personnel and patients are carefully selected in accordance with guidelines.

Å°¿öµå

Intravenous sedation; Midazolam; Nitrous oxide; Behavior management

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI